BioSpace News Archive

AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies.

LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today reported financial results for the quarter ended March 31, 2022, and highlighted recent business updates.

Black Bird Biotech, Inc. (OTC:BBBT) , manufacturer of plant-based MiteXstream TM biopesticide, today reported that a recent interview of President, Fabian Deneault, by PubCo Insight has been released.

CEL-SCI Corporation reported financial results for the quarter ended March 31, 2022, as well as key clinical and corporate developments.

Surgalign Holdings, Inc. announced that at its Annual Meeting of Stockholders on May 10, 2022, the Board and stockholders of the Company approved a reverse stock split of the Company’s issued and outstanding shares of its common stock and authorized the Board to select the ratio of the reverse stock split.

Spirovant Sciences, a gene therapy company developing treatments for respiratory diseases, including cystic fibrosis, announced the launch of its new state-of-the-art research laboratory and corporate headquarters in Philadelphia.

Inhibrx Inc. (Nasdaq: INBX), today announced topline results from a Phase 1 clinical trial evaluating the safety, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (“AATD”).

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2022, and other recent developments.

GT Biopharma, Inc. announced first quarter fiscal 2022 results for the period ended March 31, 2022.

Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 3,419,000 shares of common stock, in a private placement.